All In MedTech

Device Trial Radar · NCT07751887

Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma

Prospective Multicentric Study of Middle Meningeal Artery Embolisation Combined With Surgical Treatment for Chronic Subdural Hematoma

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Apr 1, 2029

Study completion Jun 1, 2029

Sponsor

Lead sponsor
University Hospital Hradec KraloveAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 7, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Factorial
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This international multicenter study evaluates the efficacy and safety of middle meningeal artery embolization (MMAE) using PVA particles or liquid embolic agents as a perioperative treatment to prevent the recurrence of chronic subdural hematoma (cSDH). All participating patients across centers in the Czech Republic and Slovakia will receive the minimally invasive MMAE procedure within 7 days prior to or after surgical evacuation, with the primary goal of assessing hematoma recurrence rates and procedure-related complications over a 90-day follow-up period.

Conditions

  • Chronic Subdural Hematoma

Interventions

  • Middle Meningeal Artery EmbolisationDevice

    Endovascular occlusion of the middle meningeal artery (MMA) performed under fluoroscopic guidance. The procedure aims to devascularize the chronic subdural hematoma membrane to promote hematoma resorption and prevent recurrence.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of hematoma recurrence or treatment failure requiring surgical evacuationTime frame: Up to 90 days post-enrollment.

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Ceske Budejovice

    České Budějovice, Czechia · Recruiting

  • University Hospital Hradec Kralove

    Hradec Králové, Czechia · Recruiting

  • Hospital Liberec

    Liberec, Czechia · Recruiting

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.